Loading the section
Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Ligand Pharmaceuticals Incorporated trades on Nasdaq under the ticker LGND. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks LGND has traded between 175.89 $ and 326.63 $. As of 09 October 2026 the price stood 83.53 % of the way from the 52-week low to the high.
Over one year LGND shares rose 63.59 %; over six months they rose 47.28 %. Volatility over 90 days is 32.33 %. Dividends are not included: this is price change only, as of 09 October 2026.
LGND trades at a price-to-earnings ratio of 38.2, above the sector median of 24.8. Price to sales is 21.4, above the sector median of 3.9. Price to book is 5.9, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 294.79 | 304.78 | 294.32 | 301.81 | 183,043 |
| 08 October 2026 | 290.41 | 296.48 | 281.74 | 295.00 | 318,900 |
| 07 October 2026 | 293.63 | 301.27 | 292.47 | 293.26 | 309,200 |
| 06 October 2026 | 309.41 | 309.41 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Ligand Pharmaceuticals Incorporated (LGND) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 268.1m $, net income was 124.5m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO, CA, 92121, US
Ligand Pharmaceuticals Incorporated reported revenue of 274M $ and net income of 154M $ over the last four quarters. Net margin is 55.95 %. Revenue changed by +51.24 % year over year. Earnings per share are 7.67 $. Market capitalisation is 5.9B $.
LGND has a return on equity of 15.40 %, above the sector median of −41.68 %. Return on assets is 10.02 %, above the sector median of −32.11 %. Operating margin is 34.46 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 293.73 |
| 296.94 |
| 163,700 |
| 05 October 2026 | 303.95 | 309.77 | 300.79 | 306.77 | 163,800 |
| 02 October 2026 | 307.55 | 307.63 | 301.32 | 302.96 | 179,200 |
| 01 October 2026 | 309.82 | 312.05 | 301.48 | 302.74 | 374,000 |
| 30 September 2026 | 310.52 | 317.23 | 306.95 | 312.37 | 505,900 |
| 29 September 2026 | 313.63 | 317.10 | 304.36 | 310.36 | 431,000 |
| 28 September 2026 | 299.78 | 314.94 | 299.70 | 314.10 | 239,600 |
| 25 September 2026 | 303.17 | 305.35 | 293.90 | 301.52 | 305,800 |
| 24 September 2026 | 296.95 | 303.41 | 296.37 | 299.04 | 209,400 |
| 23 September 2026 | 300.44 | 302.44 | 296.08 | 298.41 | 242,000 |
| 22 September 2026 | 291.00 | 300.48 | 289.00 | 298.50 | 308,700 |
| 21 September 2026 | 283.67 | 290.51 | 282.45 | 290.07 | 237,400 |
| 18 September 2026 | 285.63 | 285.64 | 280.49 | 283.49 | 372,800 |
| 17 September 2026 | 279.51 | 285.51 | 273.10 | 284.70 | 248,800 |
| 16 September 2026 | 277.97 | 278.74 | 271.22 | 275.20 | 299,000 |
| 15 September 2026 | 280.53 | 280.53 | 270.77 | 276.98 | 180,200 |
| 14 September 2026 | 284.93 | 287.14 | 280.12 | 280.65 | 158,800 |